PNPLA3、TM6SF2和HSD17B13变异对普通人群肝硬化和肝细胞癌风险的联合影响
研究将PNPLA3、TM6SF2和HSD17B13三个变异构建遗传风险评分(GRS,0-6分),在丹麦110,761人和英国生物银行334,691人中分析其与肝硬化和肝细胞癌(HCC)的关联。结果显示GRS越高,肝硬化及HCC风险显著增加,最高评分组肝硬化风险达12倍、HCC风险达29倍。
要点
- GRS评分5或6者较0分者肝硬化风险增加12倍(OR 12,95%CI 7.7-19)。
- GRS评分5或6者较0分者HCC风险增加29倍(OR 29,95%CI 17-51)。
- GRS与血浆ALT水平升高相关,评分5或6者较0分者ALT升高26%。
核心结论
- 脂肪肝遗传风险评分在普通人群中可带来高达12倍的肝硬化风险和29倍的HCC风险。
研究设计与样本
- 研究纳入丹麦Copenhagen队列110,761人和英国生物银行334,691人,构建基于PNPLA3 p.I148M、TM6SF2 p.E167K和HSD17B13 rs72613567的遗传风险评分(0-6分)。
主要发现
- 风险评分0、1、2、3、4、5或6的频率分别为5%、25%、41%、23%、5.5%、0.5%。
- 评分5或6者较0分者血浆ALT水平升高26%。
- Meta分析中,评分1、2、3、4、5或6者较0分者肝硬化OR分别为1.6(95%CI 1.3-1.9)、2.0(95%CI 1.8-2.2)、3.1(95%CI 2.7-3.5)、5.2(95%CI 4.2-6.4)、12(95%CI 7.7-19)。
- 对应HCC的OR分别为1.2(95%CI 0.9-1.7)、1.0(95%CI 0.7-1.3)、2.4(95%CI 1.9-3.0)、3.3(95%CI 2.2-5.0)、29(95%CI 17-51)。
关键数值与推荐
- GRS评分5或6者肝硬化OR为12(95%CI 7.7-19),HCC OR为29(95%CI 17-51),均以评分0为参照。
临床怎么用
- 在普通人群中可考虑使用该GRS评分识别肝硬化和HCC高风险个体,评分5或6者风险显著升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: We hypothesized that a genetic risk score (GRS) for fatty liver disease influences the risk of cirrhosis and hepatocellular carcinoma (HCC). Three genetic variants (patatin-like phospholipase domain-containing protein 3 [PNPLA3] p.I148M; transmembrane 6, superfamily member 2 [TM6SF2] p.E167K; and hydroxysteroid 17-beta dehydrogenase 13 [HSD17B13] rs72613567) were combined into a risk score, ranging from 0 to 6 for risk-increasing alleles. APPROACH AND RESULTS: We examined the association of the risk score with plasma markers of liver disease and with cirrhosis and HCC in 110,761 individuals from Copenhagen, Denmark, and 334,691 individuals from the UK Biobank. The frequencies of risk scores of 0, 1, 2, 3, 4, and 5 or 6 were 5%, 25%, 41%, 23%, 5.5%, and 0.5%, respectively. A higher GRS was associated with an increase in plasma alanine aminotransferase (ALT) level of 26% in those with score 5 or 6 versus 0. In meta-analysis of the Copenhagen studies and the UK Biobank, individuals with scores 1, 2, 3, 4, and 5 or 6 had odds ratios (ORs) for cirrhosis of 1.6 (95% confidence interval [CI], 1.3, 1.9), 2.0 (95% CI, 1.8, 2.2), 3.1 (95% CI, 2.7, 3.5), 5.2 (95% CI, 4.2, 6.4), and 12 (95% CI, 7.7, 19), respectively, as compared with those with a score of 0. The corresponding ORs for HCC were 1.2 (95% CI, 0.9, 1.7), 1.0 (95% CI, 0.7, 1.3), 2.4 (95% CI, 1.9, 3.0), 3.3 (95% CI, 2.2, 5.0), and 29 (95% CI, 17, 51). CONCLUSION: A GRS for fatty liver disease confers up to a 12-fold higher risk of cirrhosis and up to a 29-fold higher risk of HCC in individuals from the general population.
引用
- Gellert-Kristensen H, Richardson TG, Davey Smith G, et al. Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population. Hepatology. 2020. PMID: 32190914. doi:10.1002/hep.31238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。